secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001104659-26-038593
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Phase 2 miss for ALTO-101; shifts focus to ALTO-207
---------------------------------------------------------------------

- ALTO-101 did not meet primary EEG or cognitive endpoints in Phase 2 CIAS study.
- Near-significant theta-ITC effect (p=0.052); nominal in cognitively impaired subgroup (p=0.03).
- Company developed modified-release ALTO-101 formulation; will pursue partnerships, not further internal development.
- ALTO-207 Phase 2b in treatment-resistant depression on track for 1H 2026; cash position $275M.
- Tolerability favorable with nausea/vomiting in line with placebo; high skin reaction rates observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926038593/0001104659-26-038593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926038593/tm2610746d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-038593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer